Novel 5,6-dihydropyrazolo[3,4-E][1,4]diazepin-4 (1H)-one derivatives for the treatment of asthma and chronic obstructive pulmonary disease.
This application claims dihydropyrazolodiazepinones as phospho-diesterase 4(PDE4) inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. The compounds are shown to be potent inhibitors of PDE4B2, but no other biological data are provided. Thus, it is not clear whether these compounds provide any advantage over previously described PDE4 inhibitors or whether the issues frequently associated with PDE4 inhibitors have been addressed.